Product Center
Welcome to the Centralized Signing of the Project
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24
- Views:
(Summary description)In Taizhou in June, the fragrance of gardenias fills the air, the rain moistens everything, and the city is full of splendor. It is a good time for China Medical City, full of innovation and vitality, to enhance its new advantages in innovation and development, and to start a second entrepreneurship! Under this wave of entrepreneurship in full swing, the vigorous Ab&B Bio-Tech Co., Ltd. JS ushered in the milestone moment of the signing of its projects.
Welcome to the Centralized Signing of the Project
(Summary description)In Taizhou in June, the fragrance of gardenias fills the air, the rain moistens everything, and the city is full of splendor. It is a good time for China Medical City, full of innovation and vitality, to enhance its new advantages in innovation and development, and to start a second entrepreneurship! Under this wave of entrepreneurship in full swing, the vigorous Ab&B Bio-Tech Co., Ltd. JS ushered in the milestone moment of the signing of its projects.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24 16:06
- Views:
In Taizhou in June, the fragrance of gardenias fills the air, the rain moistens everything, and the city is full of splendor. It is a good time for China Medical City, full of innovation and vitality, to enhance its new advantages in innovation and development, and to start a second entrepreneurship! Under this wave of entrepreneurship in full swing, the vigorous Ab&B Bio-Tech Co., Ltd. JS ushered in the milestone moment of the signing of its projects.
The highlights of the projects signed this time are frequent and eye-catching. The project plans to invest an additional 1 billion yuan, focusing on promoting the preclinical research, registration application, and clinical trials of 5 innovative vaccine projects, including the new coronavirus genetic engineering vaccine, 23-valent pneumococcal polysaccharide vaccine, pneumonia conjugate vaccine, and recombinant shingles vaccine. At the same time, the company has completed the Series A financing of 300 million yuan with Shenzhen Gaotejia Investment Group, Shengshi Jintai, Guohai Venture Capital, Zhuzhou International Investment, Yida Capital, and other investment institutions to help ensure the orderly progress of the project.
Zhang Xiaobing, a member of the Standing Committee of Taizhou Municipal Party Committee and Secretary of the Party Working Committee of Taizhou Pharmaceutical High-tech Zone, proposed in his speech that all relevant departments of China Medical City will focus on creating a professional business environment with "more streamlined services", "more accurate policy support", and "faster review and approval". They will do their best to provide more convenient, high-quality, and thoughtful services for the Ab&B Bio-Tech Co., Ltd. JS project, and make every effort to promote the early start, early production, and early results of the project.
The project signing representative, Lu Bin, Deputy Director of the Pasteur Institute, Shanghai, Chinese Academy of Sciences, said about the cooperation: The cooperation between the two parties on the new coronavirus pneumonia (COVID-19) genetically engineered vaccine is to give full play to the vaccine innovation capabilities of the Pasteur Institute in Shanghai and the vaccine industrialization capability of Ab&B Bio-Tech Co., Ltd. JS, based on the current and long-term strategic cooperation. We look forward to using this cooperation as a starting point to combine production, academia, and research to accelerate the development, production, and launch of more innovative vaccines.
Wang Shuguang, the executive partner of Shenzhen Gaotejia Investment Management Group (Shanghai), on behalf of investment institutions, shared his thoughts: We are fortunate to invest in Ab&B Bio-Tech Co., Ltd. JS in 2018 and become its comrades-in-arms, partners, and fans, standing together through thick and thin. Watching Ab&B Bio-Tech Co., Ltd. JS develop from a construction site to a modern vaccine factory, from an obscure early R&D company to a rising star in the vaccine industry, I feel gratified and fulfilled. The development history of Ab&B Bio-Tech Co., Ltd. JS is like a microcosm of the development of China Medical City. We are full of confidence and expectations for China Medical City. We look forward to establishing more in-depth and long-term cooperation with China Medical City, serving more companies like Ab&B Bio-Tech Co., Ltd. JS, and contributing to China's future pharmaceutical industry.
An Youcai, Chairman/General Manager of Jiangsu Ab&B Bio-Tech Co., Ltd. JS, briefly described the four-year rapid development of Ab&B Bio-Tech Co., Ltd. JS in his speech at the signing ceremony, and expressed sincere thanks to the leaders, experts, and cooperative units at all levels who have supported, guided, and served Ab&B Bio-Tech Co., Ltd. JS on its way forward. At the same time, he also said that in the new journey of the second entrepreneurship of China Medical City, we will seize the day and night, work hard, and promote more new projects to take root, bear fruit, and become brave participants and leaders, striving for a win-win situation!
The achievements in the past are worth remembering, and we should run hard in the future. "Be encouraged in time, for time waits for no one." When we are born at the right time, we have fire in our hearts and light in our eyes. Let’s run, Ab&B Bio-Tech Co., Ltd. JS!
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
